Search clinical trials for: Fruquintinib and Everolimus

Total 270713 results

Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
Peking University First Hospital

Recruiting

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Renal Cell Carcinoma, Clear Cell, Somatic

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Hutchison Medipharma Limited

Withdrawn

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Lung Cancer

China
Zhen-Yu Ding

Completed

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） (DOFEMCRC)

Colorectal Cancer

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Fudan University

Recruiting

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Shanghai Zhongshan Hospital

Recruiting

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colo-rectal Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Peking University

Unknown

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Colorectal Cancer

China
Seung-Jung Park
Abbott Medical Devices; CardioVascular Research Foundation, Korea

Terminated

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST) (BEST)

Coronary Artery Disease

Thailand, Korea, Republic of, China, Malaysia
Tianjin Medical University Cancer Institute and...

Recruiting

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Gastric Cancer

China
Sichuan University

Unknown

Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma (FSTAMBTA)

Biliary Tract Adenocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Gastric Cancer

China
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Colorectal Cancer

China
Hutchmed

Completed

Fruquintinib Renal Impairment Study

Renal Impairment

United States
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (OSAT)

Metastatic Renal Cell Carcinoma (mRCC)

Norway
Hutchmed

Completed

A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients

Patient Safety

China
Hutchison Medipharma Limited
Fudan University

Completed

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Tumor

China
Sun Yat-sen University

Recruiting

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Colorectal Cancer Metastatic

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Huazhong University of Science and Technology

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Cancer

China
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
Junjie Peng

Not yet recruiting

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Colorectal Cancer

China
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Wuhan Union Hospital, China

Not yet recruiting

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Fudan University

Recruiting

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Carcinoma

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Weijian Guo

Not yet recruiting

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer

Gastric Cancer

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Metastatic Non-small Cell Lung Cancer

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
Immunitas Therapeutics

Recruiting

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Follicular Lymphoma | Colorectal Cancer | Hodgkin Lymphoma | Esophageal Cancer | Small Bowel Cancer | Burkitt Lymphoma | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Hormone Receptor Positive Breast Carcinoma | Cutaneous...

United States
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Guangxi Medical University

Recruiting

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer | Fruquintinib | SOX

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China

3

Subscribe